Lobe Sciences (CSE: LOBE) (OTCQB: LOBEF) (“Lobe” or the “Company”) is biotechnology company entering clinical stage development this year and is focused on transforming psychedelic medicine to benefit patients of all ages. Lobe is engaged in research and development using psychedelic and nonpsychedelic compounds targeting the 5HT2 receptor family. The company’s team is made up of biotech executives who collectively have managed the development and regulatory approval of revolutionary drugs around the globe. For more information, visit the company’s website at www.LobeSciencesir.com.
To register for the conference and view the presentation, visit https://planetmicrocapshowcase.com/
About Lobe Sciences Ltd.
Lobe Sciences is a life sciences company focused on psychedelic medicines. The company, through collaborations with industry-leading partners, is engaged in drug research and development based on psychedelic compounds targeting the 5HT2 receptor family and the development of innovative devices and delivery mechanisms to improve mental health and wellness.
For further information please contact:
Lobe Sciences Ltd.
Philip J Young, CEO
Tel: (949) 505-5623
THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, provides the online investment community with custom-built portals that include summaries on hundreds of presenting companies. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN utilizes social media and syndicated articles to maximize the visibility of various investor conferences.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com